FERAHEME delivers clinical efficacy in just 1 gram^1,2

The largest IV iron head-to-head, double-blind trial of ~2000 patients focused on incidence of hypersensitivity²

Incidence of moderate to severe HSR (including anaphylaxis) or moderate to severe hypotension²

FERAHEME was non-inferior to Injectafer^®2

	FERAHEME (n=997) Patients (%)	Injectafer® (n=1000) Patients (%)
Primary endpoint: Composite of the following:	6 (0.6%)	7 (0.7%)
Moderate hypersensitivity reaction	3 (0.3%)	6 (0.6%)
Severe hypersensitivity reaction	1 (0.1%)	0 (0.0%)
Anaphylaxis	0 (0.0%)	0 (0.0%)
Moderate hypotension	2 (0.2%)	1 (0.1%)
Severe hypotension	0 (0.0%)	0 (0.0%)

Please see Important Safety Information, including Boxed Warning.

Moderate HSR was defined as requiring minimal medical intervention or corrective treatment; severe HSR was characterized as requiring medical intervention or corrective treatment, with possible hospitalization. Anaphylaxis was defined as a sudden, severe, potentially fatal systemic allergic reaction as operationally defined using the Sampson criteria. Hypotension was defined as a >30% decrease from baseline in systolic blood pressure or a decrease of >20 mm Hg in systolic blood pressure with symptoms (dizziness/lightheadedness, fatigue, syncope, lack of consciousness, blurred vision).²

CI=confidence interval; Hgb=hemoglobin; HSR=hypersensitivity reaction; IDA=iron deficiency anemia.

back to top

In the same study, FERAHEME had a significantly lower rate of severe hypophosphatemia vs Injectafer^® (ferric carboxymaltose)^1-3

Incidence of severe hypophosphatemia (defined by blood phosphorus of <0.6 mmol/L or <2.0 mg/dL at Week 2)^1-3*

*An endpoint of severe hypophosphatemia was prespecified as serum phosphate level of <0.6 mmol/L or <2.0 mg/dL, which is defined as Grade 3 severity (severe or medically significant but not immediately life threatening; hospitalization; or prolongation of hospitalization indicated; disabling) by the Common Terminology Criteria for Adverse Events (CTCAE).³

FERAHEME demonstrated normal phosphate levels throughout the study period vs Injectafer^® (ferric carboxymaltose)^2,3

Serum phosphate levels^2,3

^†P<0.0001.

^‡Defined by blood phosphorus of <2.0 mg/dL at Week 5.⁴

One gram of FERAHEME was non-inferior to 1.5 grams of Injectafer^® (ferric carboxymaltose) with respect to Hgb rise at Week 5^1,2

Mean change in Hgb (g/dL) per full therapeutic dose^1,2

*Adjusted for difference in baseline Hgb.

Mean change in Hgb (g/dL) per gram of iron administered^1,2

Just 1 gram of FERAHEME demonstrated normal levels of mean ferritin and TSAT at Week 5 vs 1.5 grams of Injectafer^® (ferric carboxymaltose)^2,5,6

	FERAHEME (1.02 g)	Injectafer® (1.5 g)	Normal Range
Ferritin levels Mean (SD)	227.5 ng/mL (193.9 ng/mL)	397.8 ng/mL (301.2 ng/mL)	40-300 ng/mL(Male) 20-200 ng/mL(Female)
TSAT levels Mean (SD)	25.9% (11.6%)	28.6% (11.5%)	20%-50%

Select Important Safety Information: Excessive therapy with parenteral iron can lead to excess storage of iron with the possibility of iatrogenic hemosiderosis. Regularly monitor the hematologic response during parenteral iron therapy. Do not administer FERAHEME to patients with iron overload.

SD=standard deviation; TSAT=transferrin saturation.